Conundrums and Caveats in Neuroendocrine Tumors of the Pancreas

Surgical Pathology Clinics

Volumn 4, Issue 2, 2011, Pages 589-624

  Tang, Laura H ^a   Klimstra, David S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chromogranin; Endocrine; Islet cell tumor; Ki 67; Neuroendocrine; Neuroendocrine neoplasm; Neuroendocrine tumor; Pancreas; Somatostatin receptor

Indexed keywords

CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; REVIEW;

EID: 79957638056     PISSN: 18759181     EISSN: 18759157     Source Type: Journal    
DOI: 10.1016/j.path.2011.03.003     Document Type: Review

References (38)

1. Nicholls A.G. Simple adenoma of the pancreas arising from an island of langerhans. J Med Res 1902, 8:385.
2. Hruban R.H., Pitman M.B., Klimstra D. Tumor of the Pancreas. AFIP atlas of tumor pathology, Series 4 2007, American Registry of Pathology, Washington, DC. 6th edition.
3. Ferrone C.R., Tang L.H., Tomlinson J., et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?. J Clin Oncol 2007, 25(35):5609-5615.
4. Hussain S., Arwini A., Chetty R., et al. Oncocytic pancreatic endocrine neoplasms: a clinicopathologic and immunohistochemical analysis of 21 cases. Mod Pathol 2005, 18:279A.
5. Hoang M.P., Hruban R.H., Albores-Saavedra J. Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease. Am J Surg Pathol 2001, 25(5):602-609.
6. Zee S.Y., Hochwald S.N., Conlon K.C., et al. Pleomorphic pancreatic endocrine neoplasms: a variant commonly confused with adenocarcinoma. Am J Surg Pathol 2005, 29(9):1194-1200.
7. Rindi G., de Herder W.W., O'Toole D., et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: why such guidelines and how we went about It. Neuroendocrinology 2006, 84(3):155-157.
8. Kulke M.H., Anthony L.B., Bushnell D.L., et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010, 39(6):735-752.
9. Scarpa A., Mantovani W., Capelli P., et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010, 23(6):824-833.
10. Washington K, Tang LH, Berlin J, et al. Protocol for the Examination of Specimens from Patients with Carcinoma or Endocrine Pancreas. Arch Pathol Lab Med, in press.
11. Klimstra D.S., Modlin I.R., Adsay N.V., et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010, 34(3):300-313.
12. Kwekkeboom D.J., Krenning E.P., Scheidhauer K., et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009, 90(2):184-189.
13. Carrasquillo J.A., Chen C.C. Molecular imaging of neuroendocrine tumors. Semin Oncol 2010, 37(6):662-679.
14. Hicks R. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging 2010, 10(Spec no A):S83-S91.
15. Klimstra D.S. Nonductal neoplasms of the pancreas. Mod Pathol 2007, 20(Suppl 1):S94-S112.
16. Hochwald S.N., Zee S., Conlon K.C., et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002, 20(11):2633-2642.
17. Tang L.H., Shia J., Vakiani E., et al. Transforming High Grade Neuroendocrine Neoplasms (NENs) of the Enteropancreatic System-a Unique Entity Distinct from De Novo High Grade Neuroendocrine Carcinomas (HGNCa) on Pathogenesis and Clinical Behavior. Mod Pathol 2008, 21:137.
18. Shia J., Tang L.H., Weiser M.R., et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?. Am J Surg Pathol 2008, 32(5):719-731.
19. Nassar H., Albores-Saavedra J., Klimstra D.S. High-grade neuroendocrine carcinoma of the ampulla of vater: a clinicopathologic and immunohistochemical analysis of 14 cases. Am J Surg Pathol 2005, 29(5):588-594.
20. Sun W., Sneige N., Staerkel G. Comparison of endoscopic ultrasound-guided and computed tomography-guided fine needle aspiration biopsy in the diagnosis of islet cell tumor of the pancreas. Mod Pathol 2004, 17(82A). [abstract].
21. Norton J.A., Shawker T.H., Doppman J.L., et al. Localization and surgical treatment of occult insulinomas. Ann Surg 1990, 212(5):615-620.
22. Klimstra D.S., Pitman M.B., Hruban R.H. An algorithmic approach to the diagnosis of pancreatic neoplasms. Arch Pathol Lab Med 2009, 133(3):454-464.
23. American Joint Cancer Committee (AJCC) Cancer Staging Manual 2010, Springer, New York (NY). 7th edition.
24. Rindi G., Kloppel G., Alhman H., et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449(4):395-401.
25. Gortz B., Roth J., Krahenmann A., et al. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 1999, 154(2):429-436.
26. Washington M.K., Tang L.H., Berlin J., et al. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the small intestine and ampulla. Arch Pathol Lab Med 2010, 134(2):181-186.
27. Washington M.K., Tang L.H., Berlin J., et al. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the stomach. Arch Pathol Lab Med 2010, 134(2):187-191.
28. Washington M.K., Tang L.H., Berlin J., et al. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the appendix. Arch Pathol Lab Med 2010, 134(2):171-175.
29. Pellegata N.S., Sessa F., Renault B., et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994, 54(6):1556-1560.
30. Corbo V., Dalai I., Scardoni M., et al. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer 2010, 17(3):771-783.
31. Capelli P., Martignoni G., Pedica F., et al. Endocrine neoplasms of the pancreas: pathologic and genetic features. Arch Pathol Lab Med 2009, 133(3):350-364.
32. Moore P.S., Missiaglia E., Antonello D., et al. Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes Chromosomes Cancer 2001, 32(2):177-181.
33. Lubensky I.A., Pack S., Ault D., et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 1998, 153(1):223-231.
34. Chung D.C., Brown S.B., Graeme-Cook F., et al. Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res 1998, 58(16):3706-3711.
35. Floridia G., Grilli G., Salvatore M., et al. Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors. Cancer Genet Cytogenet 2005, 156(1):23-30.
36. Hu W., Feng Z., Modica I., et al. Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer 2010, 1(4):360-368.
37. Jiao Y., Shi C., Edil B.H., et al. DAXX/ATRX, MEN1 and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331(6021):1199-1203.
38. Ekeblad S., Skogseid B., Dunder K., et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008, 14(23):7798-7803.